332 related articles for article (PubMed ID: 30459941)
1. Combatting mucosal melanoma: recent advances and future perspectives.
Tyrrell H; Payne M
Melanoma Manag; 2018 Sep; 5(3):MMT11. PubMed ID: 30459941
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy and Immunotherapy for Melanoma in Japan.
Namikawa K; Yamazaki N
Curr Treat Options Oncol; 2019 Jan; 20(1):7. PubMed ID: 30675668
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study.
Saijo K; Imai H; Ouchi K; Okada Y; Sato Y; Komine K; Takahashi M; Takahashi S; Shirota H; Takahashi M; Ishioka C
Tohoku J Exp Med; 2019 May; 248(1):37-43. PubMed ID: 31105123
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
D'Angelo SP; Larkin J; Sosman JA; Lebbé C; Brady B; Neyns B; Schmidt H; Hassel JC; Hodi FS; Lorigan P; Savage KJ; Miller WH; Mohr P; Marquez-Rodas I; Charles J; Kaatz M; Sznol M; Weber JS; Shoushtari AN; Ruisi M; Jiang J; Wolchok JD
J Clin Oncol; 2017 Jan; 35(2):226-235. PubMed ID: 28056206
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA
Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633
[TBL] [Abstract][Full Text] [Related]
7. Mucosal Melanoma: a Literature Review.
Yde SS; Sjoegren P; Heje M; Stolle LB
Curr Oncol Rep; 2018 Mar; 20(3):28. PubMed ID: 29569184
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L; Qi Z; Zhang L; Guo J; Si L
Front Immunol; 2021; 12():680407. PubMed ID: 34149718
[TBL] [Abstract][Full Text] [Related]
9. Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.
Fröhlich A; Hoffmann F; Niebel D; Egger E; Kukuk GM; Toma M; Sirokay J; Bieber T; Landsberg J
Front Oncol; 2020; 10():611. PubMed ID: 32457834
[No Abstract] [Full Text] [Related]
10. An Update on Mucosal Melanoma: Future Directions.
Goldemberg DC; Thuler LCS; de Melo AC
Acta Dermatovenerol Croat; 2019 Mar; 27(1):11-15. PubMed ID: 31032785
[TBL] [Abstract][Full Text] [Related]
11. Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
Gupta M; Stukalin I; Meyers D; Goutam S; Heng DYC; Cheng T; Monzon J; Navani V
JAMA Netw Open; 2023 Jun; 6(6):e2319607. PubMed ID: 37351883
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma.
Cui C; Tang B; Guo J
Chin Clin Oncol; 2014 Sep; 3(3):36. PubMed ID: 25841462
[TBL] [Abstract][Full Text] [Related]
13. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
Jung S; Johnson DB
Oncologist; 2022 Aug; 27(8):703-710. PubMed ID: 35640549
[TBL] [Abstract][Full Text] [Related]
14. Mucosal melanomas.
Tomicic J; Wanebo HJ
Surg Clin North Am; 2003 Apr; 83(2):237-52. PubMed ID: 12744608
[TBL] [Abstract][Full Text] [Related]
15. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
Schaefer T; Satzger I; Gutzmer R
Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment with avapritinib in patient with mucosal metastatic melanoma.
Cocorocchio E; Pala L; Conforti F; Guerini-Rocco E; De Pas T; Ferrucci PF
Ther Adv Med Oncol; 2020; 12():1758835920946158. PubMed ID: 32821296
[TBL] [Abstract][Full Text] [Related]
17. Mucosal Melanoma: Epidemiology, Biology and Treatment.
Spencer KR; Mehnert JM
Cancer Treat Res; 2016; 167():295-320. PubMed ID: 26601869
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of Human Melanoma: Past, Present, Future.
Mortezaee K; Majidpoor J
Curr Med Chem; 2024 Mar; ():. PubMed ID: 38454775
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
20. Current Status and Prospects of Immunotherapy for Gynecologic Melanoma.
Anko M; Kobayashi Y; Banno K; Aoki D
J Pers Med; 2021 May; 11(5):. PubMed ID: 34065883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
